ReviewMolecules (Basel, Switzerland)2018
Natural Peptides in Drug Discovery Targeting Acetylcholinesterase.
Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers.Future medicinal chemistry · 2025Article
- Utilizing ADMET Analysis and Molecular Docking to Elucidate the Neuroprotective Mechanisms of a Cannabis-Containing Herbal Remedy (Suk-Saiyasna) in Inhibiting Acetylcholinesterase.International journal of molecular sciences · 2025Article
- Sinulariapeptide F, a new peptide from culture broth of marine-derived fungus Simplicillium sp. SCSIO 41222.The Journal of antibiotics · 2025Article
- Novel Emerging Targets Identification in Reducing Risk of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025Review
- Imidazolium salts carrying two positive charges: design, synthesis, characterization, molecular docking, antibacterial and enzyme inhibitory activities.Frontiers in cellular and infection microbiology · 2025Article
- Vigna radiata extracts in pumpkin and soya bean oil: A novel therapeutic approach for Alzheimer's disease.PloS one · 2025Article
- Haloperidol-Induced Catalepsy and Its Correlations with Acetylcholinesterase Activity in Different Brain Structures of Mice.Neurology international · 2024Article
- Article
- Proteomic analysis of the venom of Conus flavidus from Red Sea reveals potential pharmacological applications.Journal, genetic engineering & biotechnology · 2024Article
- Recent advances in the development of therapeutic peptides.Trends in pharmacological sciences · 2023Review
- Enzyme Inhibitors from Gorgonians and Soft Corals.Marine drugs · 2023Review
- Proposing novel natural compounds against Alzheimer's disease targeting acetylcholinesterase.PloS one · 2023Article
- PyPLIF HIPPOS and Receptor Ensemble Docking Increase the Prediction Accuracy of the Structure-Based Virtual Screening Protocol Targeting Acetylcholinesterase.Molecules (Basel, Switzerland) · 2022Article
- Comprehensive Analysis and Biological Characterization of Venom Components from Solitary Scoliid WaspToxins · 2021Article
- The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Anacardic Acid Complexes as Possible Agents Against Alzheimer's Disease Through Their Antioxidant, In vitro, and In silico Anticholinesterase and Ansiolic Actions.Neurotoxicity research · 2021Article
- Hydrolase-Treated Royal Jelly Attenuates HInternational journal of food science · 2021Article
- Lipopeptide Epimers and a Phthalide Glycerol Ether with AChE Inhibitory Activities from the Marine-Derived FungusMarine drugs · 2020Article
- OctoPartenopin: Identification and Preliminary Characterization of a Novel Antimicrobial Peptide from the Suckers ofMarine drugs · 2020Article
- Effect of Food Preparations on In Vitro Bioactivities and Chemical Components ofFoods (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Acetylcholinesterase-inhibitory peptide has gained much importance since it can inhibit acetylcholinesterase (AChE) and increase the availability of acetylcholine in cholinergic synapses, enhancing cholinergic transmission in pharmacological treatment of Alzheimer's disease (AD). Natural peptides have received considerable attention as biologically important substances as a source of AChE inhibitors. These natural peptides have high potential pharmaceutical and medicinal values due to their bioactivities as neuroprotective and neurodegenerative treatment activities. These peptides have attracted great interest in the pharmaceutical industries, in order to design potential peptides for use in the prophylactic and therapy purposes. Some natural peptides and their derivatives have high commercial values and have succeeded in reaching the pharmaceutical market. A large number of peptides are already in preclinical and clinical pipelines for treatment of various diseases. This review highlights the recent researches on the various natural peptides and future prospects for AD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.